CWM
DMRA

Curi Wealth Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Curi Wealth Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed – – 389
2022
Q2 		$0 Buy
+3
New +$138 ﹤0.01% 665

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Curi Wealth Management's DMRA Position: Q3 2022 in Review

Curi Wealth Management sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q3 2022, closing a stake of 3 shares.

Curi Wealth Management first reported a position in DMRA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 26 funds tracked by Wall St. Rank hold DMRA as of Q3 2022.

  • Curi Wealth Management reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Curi Wealth Management sold 3 Damora Therapeutics, Inc. Ordinary Shares shares in Q3 2022.
  • Curi Wealth Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2022 and held it in 1 quarter.
  • Curi Wealth Management's Damora Therapeutics, Inc. Ordinary Shares position peaked at $0 in Q2 2022.
  • 26 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.